Sahsen Ventures Research
Investment Thesis
Sahsen Ventures is a Seattle-based impact investment firm founded in 2016 by Bryan White and Christine White. Its stated mission is to seed and nurture mission-driven enterprises that support Earthbound life. The firm invests in both for-profit and not-for-profit organizations, on the view that some work, such as basic research, is best financed by philanthropic grants, while translational and practical implementation of new discoveries is often best scaled by for-profit companies. This blended model, grants alongside equity, is the firm's defining trait and sets it apart from a conventional venture fund. The name comes from the Pacific Northwest native word for the hummingbird, chosen for its agility, endurance and adaptability.
Focus Areas
Sahsen organizes its work into three focus areas. Life Sciences: basic research and translational development expected to advance the quality and longevity of human life. Social Justice: equal access to health, safety and education. Environment: a healthy, sustainable environment as a precondition for prosperity. A fourth portfolio category, Holdings, covers investments outside these areas made for attractive risk-adjusted returns in support of the overall mission (examples listed include Magic Leap, Illumio, Desktop Metal and Ant Group).
Stage Focus
The site does not state a stage focus. The portfolio shows early-stage biotech and technology company investments (for example A-Alpha Bio, Variant Bio, Archon Biosciences, Xaira Therapeutics), alongside later positions in companies that went public (Athira Pharma, HilleVax, Adaptimmune, Sana). Third-party profiles describe the firm as primarily Seed and early stage, but this was not confirmed on the firm's own site.
Check Size
Not disclosed. Not inferred.
Lead Tendency
Unknown. Public sources name Sahsen as one investor among several in rounds such as Variant Bio and Athira Pharma, which suggests a participant role, but no lead announcements were found.
Recent Activity
The portfolio list shows recent for-profit additions in 2025: Endolith, Harbinger Motors, Nth Cycle and Skape Bio, and 2023 to 2024 additions including Archon Biosciences, Xaira Therapeutics, Abacus Bioscience, Nido Biosciences, Proteotype Diagnostics and Mendaera. Jesse Licht joined as Partner in 2025. The firm's news page also highlights the 2024 film Bad River, a not-for-profit environmental investment. The firm appears to be actively investing, with roughly 120 organizations on the full portfolio list.
Portfolio Highlights
The full portfolio list names about 120 organizations, roughly 70 for-profit companies and 50 not-for-profits. Notable for-profit investments include Auris Health, Recursion Pharmaceuticals, Sana Biotechnology, Lyell Immunopharma, Adaptimmune, Athira Pharma, HilleVax, Icosavax, Neoleukin Therapeutics, Cyrus Biotechnology, Variant Bio, Xaira Therapeutics, Terray Therapeutics, Dyno Therapeutics, Kriya Therapeutics, 98point6, Avail Medsystems, MP Materials, Roivant Sciences, XPeng, ContextLogic (Wish) and Owl Rock. Many marked Exited have gone public or been acquired. Not-for-profit holdings include Fred Hutchinson Cancer Research Center, the Institute for Protein Design, the Brotman Baty Institute, Planned Parenthood, the Brady Center, Landesa, Forterra NW, and several film projects.
Team
- Bryan White, Co-Founder and Chief Investment Officer: Co-founder and CIO of Quadra/Quellos and later BlackRock Alternative Advisors, where he led an investment team managing $20 billion in alternatives. Advisory board roles at the University of Washington Investment Company, the Institute for Protein Design and the Brotman Baty Institute; former board member of Pomona College and Fred Hutch.
- Christine White, Co-Founder and Program Director: Background in health research and policy in nonprofit and government organizations; board governance and nonprofit program experience.
- Jesse Licht, CFA, Partner (since 2025): Managing Director in BlackRock's Hedge Fund Solutions business, formerly at Quellos; co-investment program portfolio manager.
- Siobhan Piechowski, Finance Director: Former Quellos and BlackRock fund accounting VP; ex-Ernst & Young auditor.
- Rose Hendricks, Administrative Director: Former Quellos and BlackRock paralegal.
Decision Process
Not disclosed. The firm is a small team (two co-founders, a partner and operating staff) with an investment-office structure that looks like a family office or foundation-style investor, so decisions likely sit with the founders and partner. Unconfirmed.
Founder Preferences
Mission-driven founders in life sciences, environment and social impact. Strong ties to the University of Washington and Seattle science ecosystem (protein design, precision medicine, stem cells), and a pattern of backing spinouts from those institutions.
Geographic Focus
Seattle and the Pacific Northwest are the home base, but the portfolio is national and international (UK, Denmark, China holdings; Ashesi University in Ghana).
Contact
600 University Street, Suite 3247, Seattle, WA 98101; [email protected]; +1-206-632-4700.